# Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

> **NCT01332370** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 5391 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rosiglitazone + Metformin
- **DRUG:** Sitagliptin + Metformin

## Key facts

- **NCT ID:** NCT01332370
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 5391 (ACTUAL)
- **Last updated:** 2017-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332370, "Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01332370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*